Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.

Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review / F. Atzeni, E. Grillo, I.F. Masala, P. Sarzi-Puttini, G.T. Jones. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 18:3-4(2016 Mar), pp. 154-155.

Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

P. Sarzi-Puttini;
2016-03

Abstract

Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.
Antibodies, Monoclonal; Arthritis, Psoriatic; Humans; Lung Diseases, Interstitial; Prognosis; Pulmonary Fibrosis; Spondylitis, Ankylosing; Tumor Necrosis Factor-alpha; Antirheumatic Agents
Settore MED/16 - Reumatologia
https://www.ima.org.il/FilesUpload/IMAJ/0/193/96906.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
96906.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 103.7 kB
Formato Adobe PDF
103.7 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/640571
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact